14 patients had variants in the LRRK2 gene, of which 10 pathogenic (4.5% of the cohort, 22% of positive diagnoses) and 4 classified as VUS; the p.Gly2019Ser (G2019S) was found only in 4 subjects; clinically, patients had onset over 50 years of age, with less frequent cognitive manifestations (including ICD and hallucinations) and sleep disturbances, and higher functional autonomy with less aids even with lower L-Dopa therapy doses (see Table 1 for clinical details). Here, LRRK2 is linked to Sleep disturbance.